Pyxis Oncology
Approach
Pyxis Oncology develops antibody therapeutics to promote the body‘s immune response to cancer. Leveraging new insights into the tumor microenvironment, Pyxis works to enhance the immune response against cancer—even in tumor types that historically have not responded well to cancer immunotherapies.
Pyxis (PYXS) went public in October 2021
Pyxis Oncology is addressing
CEO:
Lara Sullivan, MD
Founders:
David Steinberg
Shaan Gandhi (MD, DPhil)
John Flavin
First investment:
July 2019